Upstream anticoagulation for patients with ST-elevation myocardial infarction undergoing primary percutaneous...

Area of Science:

• Cardiology
• Interventional Cardiology
• Clinical Trials

Background:

• Optimal timing of anticoagulant administration in ST-elevation myocardial infarction (STEMI) patients undergoing primary percutaneous coronary intervention (PCI) is not well-defined.
• Understanding the impact of preprocedural anticoagulation on clinical and angiographic outcomes is crucial for STEMI management.

Purpose of the Study:

• To assess the relationship between preprocedural anticoagulation use and clinical and angiographic outcomes in STEMI patients undergoing primary PCI.
• To evaluate the impact of preprocedural anticoagulation on procedural success and one-year clinical outcomes.

Main Methods:

• Analysis of data from the TOTAL trial, stratifying 10,064 patients based on preprocedural parenteral anticoagulant use before PCI.
• Comparison of baseline and procedural characteristics between groups.
• Use of Cox proportional modeling and logistic regression, adjusted for propensity scores, to analyze one-year clinical and angiographic outcomes.

Main Results:

• Preprocedural anticoagulation was administered to 63% of patients, most commonly intravenous unfractionated heparin.
• Patients receiving preprocedural anticoagulation showed improved TIMI flow and reduced thrombus burden before PCI.
• Associated with decreased use of bailout thrombectomy, GP IIb/IIIa inhibitors, and intra-aortic balloon pump, as well as lower rates of CABG and minor bleeding at one year.

Conclusions:

• Preprocedural anticoagulation improves angiographic outcomes, including blood flow and thrombus reduction, prior to PCI in STEMI patients.
• Associated with reduced need for bailout procedures during PCI.
• No significant difference in major adverse cardiovascular events such as death, recurrent infarction, or heart failure at one year was observed.